Assembly of nuclear dimers of PI3K regulatory subunits is regulated by the Cdc42-activated tyrosine kinase ACK.
Clayton, Natasha S
Vicenté-Garcia, Jose J
Schroeder, Courtney M
Littlewood, Trevor D
Wilde, Jonathon I
Brown, Murray JB
Mott, Helen R
J Biol Chem
MetadataShow full item record
Clayton, N. S., Fox, M., Vicenté-Garcia, J. J., Schroeder, C. M., Littlewood, T. D., Wilde, J. I., Krishnan, K., et al. (2022). Assembly of nuclear dimers of PI3K regulatory subunits is regulated by the Cdc42-activated tyrosine kinase ACK.. J Biol Chem https://doi.org/10.1016/j.jbc.2022.101916
Activated Cdc42-associated kinase (ACK) is an oncogenic nonreceptor tyrosine kinase associated with poor prognosis in several human cancers. ACK promotes proliferation, in part by contributing to the activation of Akt, the major effector of class 1A phosphoinositide 3-kinases (PI3Ks), which transduce signals via membrane phosphoinositol lipids. We now show that ACK also interacts with other key components of class 1A PI3K signaling, the PI3K regulatory subunits. We demonstrate ACK binds to all five PI3K regulatory subunit isoforms and directly phosphorylates p85α, p85β, p50α, and p55α on Tyr607 (or analogous residues). We found that phosphorylation of p85β promotes cell proliferation in HEK293T cells. We demonstrate that ACK interacts with p85α exclusively in nuclear-enriched cell fractions, where p85α phosphorylated at Tyr607 (pTyr607) also resides, and identify an interaction between pTyr607 and the N-terminal SH2 domain that supports dimerization of the regulatory subunits. We infer from this that ACK targets p110-independent p85 and further postulate that these regulatory subunit dimers undertake novel nuclear functions underpinning ACK activity. We conclude that these dimers represent a previously undescribed mode of regulation for the class1A PI3K regulatory subunits and potentially reveal additional avenues for therapeutic intervention.
This research was supported by: BBSRC DTG/A studentships (BB/F017464/1 and BB/A517685/1) to NSC and JV-G; an MRC iCASE (MR/N018354/1) to DO and CC; a Churchill Scholarship (awarded by the Winston Churchill Foundation of the United States) to CS; a CR-UK (C4750/A19013) programme grant to TDL; a National Overseas Scholarship, Government of India and a Cambridge Commonwealth Scholarship to KK and a CR-UK project grant (C11309/A5148) to DO and HRM.
Medical Research Council (1789868)
External DOI: https://doi.org/10.1016/j.jbc.2022.101916
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335930
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc-nd/4.0/